Asda Selects Blue Yonder’s Order Management to Accelerate its Omni-Channel Transformation
24.5.2022 13:00:00 EEST | Business Wire | Press release
Having selected Blue Yonder last year to digitally transform its end-to-end supply chain and retail operations, Asda, one of Britain’s leading retailers with a unique position in the market, is continuing its retail transformation journey with Blue Yonder by selecting Luminate® Commerce solutions to modernize its order management capabilities. Asda will also partner with Bringg, a Blue Yonder technology alliance partner and the leading delivery and fulfillment cloud platform, to make each element of the supply chain seamless, connected and orchestrated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005263/en/
Asda consists of supercenters, superstores, and smaller supermarkets. The retailer also runs petrol filling stations and Asda Living stores, which offer its popular George clothing and home merchandise lines. The company employs more than 140,000 colleagues serving more than 16 million customers who shop in its stores and online weekly.
With Blue Yonder’s order management (OMS) microservices, Asda will be able to:
- Process orders faster to improve the customer experience.
- Provide customers with real-time inventory visibility from the beginning of the shopping experience, as well as pre-sourcing fulfillment options.
- Connect with the entire supply chain, considering the capacity to fulfill demand across any channel, at any time.
- Provide dynamic slotting options to the end customer for both home deliveries and pickup in store.
“Omni-channel is at the heart of our strategy and customer proposition, where we want to provide a great customer experience and a seamless user journey. We have been extremely impressed by Blue Yonder’s OMS microservices, which we will deploy across our grocery, clothing and general merchandise segments,” said Carl Dawson, chief information officer, Asda.
Blue Yonder’s flexible OMS microservices, powered by machine learning and artificial intelligence, will help Asda optimize the entire click-to-deliver journey, starting with an engaging customer experience through efficient order fulfillment. With Bringg, Asda will be able to optimize its last-mile operations to deliver on-time to meet customer expectations. The combination will support Asda’s home delivery service, click and collect proposition, as well as new channels such as express commerce platforms.
“Asda is leading a game-changing retail transformation focused on customer centricity, from first to last mile. We are very excited to extend our relationship with Asda into an area where we are connecting e-commerce with a true omni-channel landscape. Our modern OMS microservices are engineered to scale, perform and operate under the highest volumes seen on the market. Our OMS microservices, SaaS native, API-first components leverage the latest technology and engineering to speed up our clients’ transformations. We believe that this will help Asda to continue to modernize its business and invest in customer proposition,” said Gael Ramaen, vice president, commerce, Blue Yonder.
“The challenges and complexities of faster, more convenient and on-demand order orchestration, delivery and fulfillment are grand,” said Nikolai Avrutov, vice president Alliances, Bringg. “In order to achieve game-changing capabilities on these fronts, retailers need their technology vendors to work closely together and to relentlessly raise the bar for its mutual customers through tight collaboration and strategic co-innovation. We are proud to be doing just that with Blue Yonder for Asda.”
Additional Resources:
- Learn more about Luminate Commerce and the order management (OMS) microservices
- Learn how migrating to the cloud can digitally transform your supply chain
- Learn how Bringg’s Delivery Hub transforms your delivery orchestration with ease
About Asda Stores Ltd.
Founded in the 1960s in Yorkshire, Asda is the UK’s third largest supermarket and was acquired by the Issa Brothers and TDR Capital Ltd in 2021.
Each week more than 16 million customers visit its 640 stores - including Supercentres, Superstores, Supermarkets, Asda Living stores, and standalone petrol stations - and are served by over 140,000 colleagues. www.asda.com and www.george.com deliver to 99% of the UK’s homes and to its 538 click and collect sites across the UK.
Its main office is in Leeds, Yorkshire and its George clothing division is in Lutterworth, Leicestershire.
About Bringg
Bringg helps enterprises scale up and optimize their logistics operations with our data-led delivery and fulfillment cloud platform. Using Bringg, retailers and logistics providers can rapidly enable innovative delivery and fulfillment models that maximize the customer experience, optimize logistics operations and scale business channels for growth. Some of the world’s best-known brands in more than 50 countries use Bringg’s platform to deliver the perfect last mile experience at peak efficiency across multiple delivery models. https://www.bringg.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain and omni-channel commerce fulfillment. Our intelligent, end-to-end platform enables retailers, manufacturers and logistics providers to seamlessly predict, pivot and fulfill customer demand. With Blue Yonder, you can make more automated, profitable business decisions that deliver greater growth and re-imagined customer experiences. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005263/en/
Contact information
Blue Yonder: Marina Renneke, APR, +1 480-308-3037, marina.renneke@blueyonder.com
Bringg: Ashleigh Farber, +972542332099, ashleigh@bringg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
